About Physiogenex
Physiogenex is a Healthcare company based in Labege (France) founded in 2002. It operates as a preclinical CRO services for metabolic disorders are offered. Physiogenex offers products and services including In Vitro Assays, In Vivo Metabolic Studies, and Consulting Services. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Metabolic Disease. Its legal entity is PHYSIOGENEX S.A.S. Its competitors include GSK, Avidity Biosciences, Vividion Therapeutics, Korro Bio and Sutro Biopharma and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Founded in 2002, Physiogenex operates as a preclinical contract research organization based in Labege, France, with specialization in metabolic disorders. Expertise is applied to various animal models, including those for Type 2 diabetes, dyslipidemia, atherosclerosis, non-alcoholic steatohepatitis, obesity, and immunometabolic conditions. Nutritional, genetic, and transgenic models such as DIO rodents, obob mice, ApoE-KO mice, and NASH-induced hamsters are utilized in research operations.
- Headquarters Labege, France
- SectorsHealthcare
- Website physiogenex.com
- Legal Name Physiogenex S.A.S.
- Latest Funding Round$343.8K (USD), Grant
Sep 2010
- Investors
Products & Services of Physiogenex
Physiogenex offers a comprehensive portfolio of products and services, including In Vitro Assays, In Vivo Metabolic Studies, and Consulting Services.
Conducts assays for metabolic disorder analysis and drug testing.
Evaluates drug efficacy in animal models for obesity and diabetes.
Offers expertise in designing metabolic disease studies.
Funding Insights of Physiogenex
- Total Rounds 3
- Last Round Grant — $343,796
- First Round $880,680
(Sep 2006)
- Investors Count 1
All 3 funding rounds of Physiogenex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Physiogenex
Physiogenex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Physiogenex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Physiogenex
3 dated milestones of Physiogenex across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Physiogenex is founded.
- Funding First funding round of $881K.
- Funding Latest funding round, Grant, of $344K.
Competitors of Physiogenex
Physiogenex has 9 listed competitors in our database, 8 of them funded. They include GSK, Avidity Biosciences, Vividion Therapeutics, Korro Bio and Sutro Biopharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Physiogenex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Physiogenex (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Physiogenex
Complete news archive for Physiogenex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Physiogenex
Physiogenex was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Physiogenex is headquartered in Labege, France. It is registered at Labege, Haute-garonne, France.
Founded in 2002, Physiogenex operates as a preclinical contract research organization based in Labege, France, with specialization in metabolic disorders. Expertise is applied to various animal models, including those for Type 2 diabetes, dyslipidemia, atherosclerosis, non-alcoholic steatohepatitis, obesity, and immunometabolic conditions. Nutritional, genetic, and transgenic models such as DIO rodents, obob mice, ApoE-KO mice, and NASH-induced hamsters are utilized in research operations.
Physiogenex's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Physiogenex offers In Vitro Assays, In Vivo Metabolic Studies, and Consulting Services.
Physiogenex has 1 investor. Key investors include HHS.
Physiogenex operates through Physiogenex S.A.S..